Alexia Iasonos

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma
    Alexia Iasonos
    Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Cancer 119:1816-22. 2013
  2. pmc Interplay of priors and skeletons in two-stage continual reassessment method
    Alexia Iasonos
    Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, USA
    Stat Med 31:4321-36. 2012
  3. pmc The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials
    Alexia Iasonos
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Clin Cancer Res 18:5179-87. 2012
  4. pmc Identifying clinical improvement in consolidation single-arm phase 2 trials in patients with ovarian cancer in second or greater clinical remission
    Alexia Iasonos
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Gynecol Cancer 22:63-9. 2012
  5. pmc Incorporating lower grade toxicity information into dose finding designs
    Alexia Iasonos
    Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Trials 8:370-9. 2011
  6. pmc A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies
    Alexia Iasonos
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Trials 5:465-77. 2008
  7. doi request reprint Estimating the dose-toxicity curve in completed phase I studies
    Alexia Iasonos
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Stat Med 30:2117-29. 2011
  8. doi request reprint How to build and interpret a nomogram for cancer prognosis
    Alexia Iasonos
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 E 63rd St, 3rd Floor, New York, NY 10021, USA
    J Clin Oncol 26:1364-70. 2008
  9. pmc Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy
    Andrea B Apolo
    Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Natl Cancer Inst 105:499-503. 2013
  10. doi request reprint The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum
    Oliver Zivanovic
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 116:351-7. 2010

Detail Information

Publications68

  1. ncbi request reprint External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma
    Alexia Iasonos
    Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Cancer 119:1816-22. 2013
    ..By using an independent, pooled, multi-institutional, international patient cohort, the authors validated a recently proposed ULMS nomogram...
  2. pmc Interplay of priors and skeletons in two-stage continual reassessment method
    Alexia Iasonos
    Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, USA
    Stat Med 31:4321-36. 2012
    ..In general, because this information is not available, we recommend that the design of two-stage trials utilize stage‚ÄČ1 data to establish a skeleton...
  3. pmc The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials
    Alexia Iasonos
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Clin Cancer Res 18:5179-87. 2012
    ....
  4. pmc Identifying clinical improvement in consolidation single-arm phase 2 trials in patients with ovarian cancer in second or greater clinical remission
    Alexia Iasonos
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Gynecol Cancer 22:63-9. 2012
    ..We illustrate how the duration of second-line therapy (SLT), the time on the investigational therapy (IT), and patient enrollment plan can affect efficacy measures from maintenance trials and might result in underpowered studies...
  5. pmc Incorporating lower grade toxicity information into dose finding designs
    Alexia Iasonos
    Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Trials 8:370-9. 2011
    ..Some authors have argued that it may be more appropriate to consider a polytomous rather than dichotomous response...
  6. pmc A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies
    Alexia Iasonos
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Trials 5:465-77. 2008
    ..From a practical perspective, clinicians are interested in designs that can estimate the MTD using fewer patients for a fixed number of doses, or can test more dose levels for a given sample size...
  7. doi request reprint Estimating the dose-toxicity curve in completed phase I studies
    Alexia Iasonos
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Stat Med 30:2117-29. 2011
    ..Confidence intervals around the toxicity probabilities at each dose level are estimated using the cumulative toxicity data. A programming code is included...
  8. doi request reprint How to build and interpret a nomogram for cancer prognosis
    Alexia Iasonos
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 E 63rd St, 3rd Floor, New York, NY 10021, USA
    J Clin Oncol 26:1364-70. 2008
    ..This guide provides a nonstatistical audience with a methodological approach for building, interpreting, and using nomograms to estimate cancer prognosis or other health outcomes...
  9. pmc Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy
    Andrea B Apolo
    Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Natl Cancer Inst 105:499-503. 2013
    ..69) and 0.58 (95% CI = 0.52 to 0.65), respectively, with superiority of the four-variable model compared with the MSKCC risk-score model for OS (the U statistic and its standard deviation were used to calculate the two-sided P = .02)...
  10. doi request reprint The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum
    Oliver Zivanovic
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 116:351-7. 2010
    ....
  11. ncbi request reprint Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract
    Matthew D Galsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 69:255-9. 2007
    ..A unifying feature of these malignancies is their aggressive course and poor outcome with standard chemotherapeutic regimens. Given the rarity of these tumors, no prospective data are available to guide management...
  12. ncbi request reprint A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma
    Vicky Makker
    Memorial Sloan Kettering Cancer Center Department of Medicine, Gynecologic Medical Oncology Service, New York, NY, USA
    Gynecol Oncol 111:249-54. 2008
    ..To determine the progression-free survival (PFS) and overall survival (OS) in a cohort of patients who received either platinum-based chemotherapy with or without radiation therapy (pelvic or WAI), or RT alone...
  13. pmc Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer
    Arjun V Balar
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 31:724-30. 2013
    ..This trial evaluated the efficacy and safety of bevacizumab with GCa in advanced UC...
  14. pmc Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer
    Oliver Zivanovic
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    Gynecol Oncol 115:209-14. 2009
    ..To analyze whether serum CA-125 response to cytoreductive surgery before initiation of postoperative chemotherapy is associated with progression-free survival (PFS) in patients with stage IIIC ovarian carcinoma...
  15. doi request reprint The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment
    Roisin O'Cearbhaill
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 116:326-31. 2010
    ....
  16. doi request reprint A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma
    Oliver Zivanovic
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer 118:660-9. 2012
    ..The objective of the current study was to develop and validate a novel, clinically relevant, individualized prognostic model for patients with uterine LMS...
  17. ncbi request reprint Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy
    Ethan Basch
    Department of Epidemiology and Biostatistics, and the Office of the Physician in Chief, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:5374-80. 2007
    ..In cancer treatment trials, clinicians traditionally report patient toxicity symptoms. Alternatively, patients could provide this information directly...
  18. ncbi request reprint Redefining stage I endometrial cancer: incorporating histology, a binary grading system, myometrial invasion, and lymph node assessment
    Joyce N Barlin
    Gynecology Service, Department of Surgery, Department of Pathology, and Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY Weill Cornell Medical College, New York, NY Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY and Department of Pathology and Molecular Genetics and Research Laboratory, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLLEIDA, Lleida, Spain
    Int J Gynecol Cancer 23:1620-8. 2013
    ..We propose a new staging system for stage I endometrial cancer and compare its performance to the 1988 and 2009 International Federation of Gynecology and Obstetrics (FIGO) systems...
  19. pmc Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009
    Vicky Makker
    Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College, New York, NY, USA
    Int J Gynecol Cancer 23:929-34. 2013
    ..Our goal was to investigate the activity of doxorubicin in the second-line setting in patients who progressed after paclitaxel/carboplatin adjuvant treatment...
  20. ncbi request reprint CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy
    Margrit M Juretzka
    Gynecology Oncology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 104:176-80. 2007
    ..A secondary objective was to assess the relationship of CA125 level to PFS...
  21. pmc Classification and regression tree (CART) analysis of endometrial carcinoma: Seeing the forest for the trees
    Joyce N Barlin
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 130:452-6. 2013
    ....
  22. ncbi request reprint Treatment patterns of FIGO Stage IB2 cervical cancer: a single-institution experience of radical hysterectomy with individualized postoperative therapy and definitive radiation therapy
    Oliver Zivanovic
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Gynecol Oncol 111:265-70. 2008
    ..The treatment of FIGO stage IB2 cervical cancer is controversial. Our aim was to assess treatment patterns, outcomes, and complications in patients with stage IB2 cervical cancer...
  23. pmc Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the international Federation of gynecology and obstetrics and american joint committee on cancer staging systems
    Oliver Zivanovic
    Department of Medicine, Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Clin Oncol 27:2066-72. 2009
    ..We aimed to determine whether the American Joint Committee on Cancer (AJCC) soft tissue sarcoma (STS) staging system is more accurate in predicting progression-free survival (PFS) and overall survival (OS)...
  24. doi request reprint Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium
    Matthew I Milowsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Clin Oncol 27:4062-7. 2009
    ..This study sought to evaluate the efficacy and to additionally define toxicity...
  25. ncbi request reprint Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function
    Matthew D Galsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 109:549-55. 2007
    ..The safety and activity of a dose-dense carboplatin-based regimen in this patient population were explored...
  26. pmc Renal cell carcinoma in young and old patients--is there a difference?
    R Houston Thompson
    Department of Surgery Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Urol 180:1262-6; discussion 1266. 2008
    ..We reviewed our experience with young patients with renal cell carcinoma and compared them to their older counterparts...
  27. doi request reprint Patterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors
    Karin K Shih
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 119:270-3. 2010
    ..The objective of this study was to evaluate patterns of recurrence and prognostic factors as well as the role of adjuvant chemotherapy in stage II-IV ovarian SBT...
  28. pmc Consolidation strategies in ovarian cancer: observations for future clinical trials
    Paul Sabbatini
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 116:66-71. 2010
    ..CONCLUSION.: Preliminary benchmarks for efficacy endpoints are suggested for future consolidation trials of patients in cCR. However, the suggested strategies will require validation in randomized trials and larger data sets...
  29. pmc Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: a 2-cohort, phase 2 study
    Martee L Hensley
    Department of Medicine, Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York 10065, USA
    Cancer 118:2403-10. 2012
    ..In this study, the authors assessed the efficacy of eribulin in platinum-resistant and platinum-sensitive recurrent ovarian cancer...
  30. doi request reprint Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors
    Roisin O'Cearbhaill
    Department of Medicine, Gynecology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 116:424-9. 2010
    ..Aromatase inhibitors are sometimes used in the treatment of selected patients with uterine leiomyosarcoma (LMS), but there are few data assessing the efficacy of aromatase inhibitors in this setting...
  31. pmc The revised 2009 FIGO staging system for endometrial cancer: should the 1988 FIGO stages IA and IB be altered?
    Nadeem R Abu-Rustum
    Department of Surgery, Gynecology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Int J Gynecol Cancer 21:511-6. 2011
    ..We sought to describe the overall survival (OS) of women with stage I endometrial cancer and examine how the estimated stage-specific OS is altered in the 2009 system...
  32. ncbi request reprint Treatment outcomes in completely resected stage I to stage IV uterine carcinosarcoma with rhabdomyosarcoma differentiation
    Vicky Makker
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center Department of Medicine, Weill Cornell Medical College Department of Epidemiology and Biostatistics, and Department of Gynecologic Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
    Int J Gynecol Cancer 23:1635-41. 2013
    ..To evaluate overall survival (OS) and progression-free survival (PFS) after adjuvant therapy in stage I to stage IV uterine carcinosarcoma with rhabdomyosarcoma differentiation...
  33. ncbi request reprint The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer
    Oliver Zivanovic
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave New York, NY 10021, USA
    Gynecol Oncol 108:287-92. 2008
    ..To analyze the impact of bulky upper abdominal disease (UAD) cephalad to the greater omentum on surgical outcomes for patients with stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal carcinoma...
  34. doi request reprint Impact of operative start time on surgical outcomes in patients undergoing primary cytoreduction for advanced ovarian cancer
    Edward J Tanner
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 126:58-63. 2012
    ..To evaluate the impact of operative start time (OST) on surgical outcomes in patients with advanced ovarian cancer...
  35. pmc Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer
    Jason A Konner
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 29:4662-8. 2011
    ..Bevacizumab prolongs progression-free survival (PFS) when included in first-line IV chemotherapy. In this study, the safety and feasibility of adding bevacizumab to a first-line IP regimen were assessed...
  36. doi request reprint A 2-year prospective study assessing the emotional, sexual, and quality of life concerns of women undergoing radical trachelectomy versus radical hysterectomy for treatment of early-stage cervical cancer
    Jeanne Carter
    Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 119:358-65. 2010
    ..To prospectively assess and describe the emotional, sexual, and QOL concerns of women with early-stage cervical cancer undergoing radical surgery...
  37. pmc Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes
    Ethan Basch
    Health Outcomes Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 East 63rd St, New York, NY 10065, USA
    J Natl Cancer Inst 101:1624-32. 2009
    ..Patient self-reporting has been proposed as an additional data source, but the implications of such a shift are not understood...
  38. doi request reprint Sequential adjuvant chemotherapy after surgical resection of high-risk urothelial carcinoma
    David J Gallagher
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer 115:5193-201. 2009
    ..The objective of this study was to evaluate the feasibility and survival impact of adjuvant, sequential chemotherapy in patients with high-risk UC...
  39. ncbi request reprint A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission
    Douglas Levine
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 110:2448-56. 2007
    ..The current study was conducted to determine the effect of goserelin and bicalutamide on progression-free survival (PFS) in patients with epithelial ovarian cancer who were in second or greater complete disease remission...
  40. doi request reprint Is there a therapeutic impact to regional lymphadenectomy in the surgical treatment of endometrial carcinoma?
    Nadeem R Abu-Rustum
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Am J Obstet Gynecol 198:457.e1-5; discussion 457.e5-6. 2008
    ..The objective of the study was to evaluate whether surgical removal of regional lymph nodes influences the overall survival of women with endometrial carcinoma...
  41. doi request reprint Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset
    Karuna Garg
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Am J Surg Pathol 33:1869-77. 2009
    ..Although young EC patients are at increased risk for synchronous endometrioid ovarian carcinomas, this does not seem to be associated with MMR loss...
  42. doi request reprint Low risk of complications associated with the fenestrated peritoneal catheter used for intraperitoneal chemotherapy in ovarian cancer
    Destin Black
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 109:39-42. 2008
    ..p.) chemotherapy for ovarian cancer. Because of recent reports of higher rates of catheter complications, we performed this study to update our experience with the fenestrated catheter...
  43. ncbi request reprint BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer
    Rachel N Grisham
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer 119:548-54. 2013
    ..In the current study, the authors sought to determine whether BRAF or KRAS mutation status was associated with disease stage and/or histology in patients with SB and LGS ovarian cancer...
  44. doi request reprint Colorectal stents for palliation of large-bowel obstructions in recurrent gynecologic cancer: an updated series
    Aileen Caceres
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Gynecol Oncol 108:482-5. 2008
    ..Our objective was to review and update our experience with colonic stent placement for patients presenting with a large-bowel obstruction due to recurrent gynecologic malignancy...
  45. doi request reprint Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma
    John Gerecitano
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York 10065, USA
    Clin Cancer Res 17:2493-501. 2011
    ....
  46. ncbi request reprint Effect of perioperative venous thromboembolism on survival in ovarian, primary peritoneal, and fallopian tube cancer
    Destin Black
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Gynecol Oncol 107:66-70. 2007
    ..The purpose of this study was to describe the overall survival of patients with ovarian, primary peritoneal, and fallopian tube cancers treated for VTE within 30 days of initial surgery...
  47. ncbi request reprint Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer
    Paul Sabbatini
    Memorial Sloan Kettering Cancer Center, New York, New York, Franklin Square Hospital, Baltimore, MD, USA, and University of Marburg, Germany
    Clin Cancer Res 12:5503-10. 2006
    ....
  48. doi request reprint Gemcitabine for advanced endometrial cancer: a retrospective study of the Memorial sloan-Kettering Cancer Center experience
    Rachel Nicole Grisham
    Gynecologic Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Gynecol Cancer 22:807-11. 2012
    ..We performed a retrospective study to determine the progression-free survival and response rate of endometrial cancer patients treated with gemcitabine at Memorial Sloan-Kettering Cancer Center...
  49. pmc Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer
    David M Hyman
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Cancer 118:3703-9. 2012
    ..The objective of the current study was to examine whether BRCA1-associated and BRCA2-associated ovarian cancers were associated with different outcomes...
  50. ncbi request reprint Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer
    Catherine S M Diefenbach
    Gynecologic Medical Oncology, Department of Medicine, Howard 903, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Gynecol Oncol 104:435-42. 2007
    ..In this study, we examined the frequency of serum elevation as well as the diagnostic and prognostic significance of this serum marker in endometrial cancer...
  51. doi request reprint External validation of a nomogram predicting overall survival of patients diagnosed with endometrial cancer
    Stephan Polterauer
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 125:526-30. 2012
    ..The aim of this study was to test the validity of the MSKCC endometrial cancer nomogram using an independent, external patient cohort...
  52. ncbi request reprint Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer
    Paul J Sabbatini
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 13:4170-7. 2007
    ....
  53. ncbi request reprint Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer
    Rachel N Grisham
    Gynecologic Medical Oncology Service, Department of Medicine, Human Oncology and Pathogenesis Program, Department of Radiology, Department of Epidemiology and Biostatistics, and Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
    Int J Gynecol Cancer 24:1010-4. 2014
    ..The objective of this study was to determine the response rate to bevacizumab with or without concurrent chemotherapy in patients with recurrent serous borderline or LGS ovarian or primary peritoneal cancer...
  54. ncbi request reprint Squamous cell carcinoma arising in mature cystic teratoma of the ovary: a case series and review of the literature
    Lisa Dos Santos
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Gynecol Oncol 105:321-4. 2007
    ..The prognosis is generally poor when disease has spread beyond the ovary. We conducted this study to review our experience with this disease and describe our current treatment modality...
  55. pmc Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers
    David M Hyman
    Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 123:196-9. 2011
    ..To evaluate the efficacy of topoisomerase I inhibitor, topotecan, in patients with recurrent BRCA+ versus BRCA- ovarian, fallopian tube, and primary peritoneal carcinomas...
  56. doi request reprint Novel monoclonal antibodies against the proximal (carboxy-terminal) portions of MUC16
    Thapi Dharma Rao
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Appl Immunohistochem Mol Morphol 18:462-72. 2010
    ..Development of such antibodies may be useful for the characterization of MUC16 biology and allow for future studies in targeted therapy and diagnostics...
  57. doi request reprint Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission
    Catherine S M Diefenbach
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 14:2740-8. 2008
    ..In this study, we describe the effects of vaccination with the HLA-A*0201-restricted NY-ESO-1b peptide on patients with epithelial ovarian cancer in high-risk first remission...
  58. doi request reprint Design considerations for dose-expansion cohorts in phase I trials
    Alexia Iasonos
    Alexia Iasonos, Memorial Sloan Kettering Cancer Center, New York, NY and John O Quigley, Universite Paris VI, Paris, France
    J Clin Oncol 31:4014-21. 2013
    ..This article provides investigators of phase I protocols with methodological tools to monitor safety and/or efficacy for patients accrued during the expansion phase and to update or confirm the established MTD. ..
  59. pmc Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma
    Craig H Moskowitz
    Departments of Medicine, Radiology, Pathology, and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Clin Oncol 28:1896-903. 2010
    ..Outside of a clinical trial, we recommend biopsy confirmation of an abnormal interim FDG-PET scan before changing therapy...
  60. ncbi request reprint Formulas calculating creatinine clearance are inadequate for determining eligibility for Cisplatin-based chemotherapy in bladder cancer
    Ganesh V Raj
    Department of Urology, 353 E 68th St, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:3095-100. 2006
    ..We hypothesize these formulas may underestimate measured CrCl, and therefore the eligibility for cisplatin-based chemotherapy...
  61. ncbi request reprint Lysophosphatidic acid acyltransferase-beta (LPAAT-beta) is highly expressed in advanced ovarian cancer and is associated with aggressive histology and poor survival
    Catherine S M Diefenbach
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 107:1511-9. 2006
    ..The significance of tumor overexpression of LPAAT-beta was investigated in a large number of advanced- and early-stage EOC patients...
  62. pmc Evaluation of an online platform for cancer patient self-reporting of chemotherapy toxicities
    Ethan Basch
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Am Med Inform Assoc 14:264-8. 2007
    ..Ongoing multi-center research will evaluate the impact of this approach on clinical and administrative outcomes...
  63. doi request reprint A pilot study using the Gynecologic Cancer Lymphedema Questionnaire (GCLQ) as a clinical care tool to identify lower extremity lymphedema in gynecologic cancer survivors
    Jeanne Carter
    Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 117:317-23. 2010
    ..This study aimed to determine the feasibility and efficacy of using the Gynecologic Cancer Lymphedema Questionnaire (GCLQ) as a symptom scale for lymphedema of the lower extremity (LLE)...
  64. ncbi request reprint Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study
    Ethan Basch
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Lancet Oncol 7:903-9. 2006
    ..We aimed to compare the reporting of symptom severity reported by patients and clinicians...
  65. ncbi request reprint Predicting the histology of renal masses using preoperative Doppler ultrasonography
    Ganesh V Raj
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 177:53-8. 2007
    ..Since conventional clear cell carcinomas are highly vascular, we used preoperative color and/or power Doppler ultrasonography to evaluate the association between vascular flow in a renal mass and surgical pathology...
  66. ncbi request reprint The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center
    Nadeem R Abu-Rustum
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 103:714-8. 2006
    ..To describe the incidence of symptomatic postoperative lower-extremity lymphedema in women treated for uterine corpus cancer, and to evaluate its relationship to regional lymph node removal and postoperative therapy...
  67. ncbi request reprint Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma
    Matthew D Galsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Joan and Sanford Weill Medical College of Cornell University, New York, NY 10021, USA
    Invest New Drugs 25:265-70. 2007
    ..The purpose of this single-center phase II study was to determine the activity of pemetrexed administered as second-line therapy in patients with advanced urothelial carcinoma...
  68. pmc Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials
    Michelle L Harrison
    Department of Gynaecology, The Royal Marsden Hospital, London, UK
    Gynecol Oncol 106:469-75. 2007
    ....